| 영문 | serum enzyme | 한글 | 혈청효소 |
|---|---|---|---|
| 설명 | 혈청 내에 포함되어 있는 여러 가지 효소를 일컫는 말이다. |
||
| 영문 | enzyme | 한글 | 효소 |
|---|---|---|---|
| 설명 | 생물체 세포속에서 합성되고, 주로 세포내에서 진행되는 화학반응을 촉매하는 단백질로 시험관내에서도 같은 촉매작용을 한다. 이 효소는 인공적으로 만든 어떤 촉매제보다 그 특이성과 촉매작용이 탁월한 특별한 생체분자이다. 신진대사, 즉 세포내에서 일어나는 물질의 화학적 변환은 효소의 작용에 의해 매우 빠르고 원할하게 이루어진다. 이것은 효소의 촉매 효율이 높은 점과 효소의 기질 특이성 때문이다. 효소반응은 상온, 상압, 최적 pH 등 적절한 조건 아래에서 진행된다. 또 효소의 주체가 단백질이기 때문에 단백질을 변성시키는 열, 강산, 강알칼리, 유기용매 등에 의해 그 작용을 잃는다. 효소는 생체에 널리 분포하며, 복잡하고 다양한 대사반응을 촉매하기 때문에 종류도 많다. 앞서 말한 바와 같이 대부분의 효소는 세포내에 존재하지만, 혈액과 그외의 간질액에 들어 있기도 하고 소화효소류처럼 체외로 분비되는 것도 있다. |
||
| 영문 | enzyme-linked immunoabsorbent assay | 한글 | 효소면역측정법 |
|---|---|---|---|
| 설명 | 효소결합면역흡착제 검정법으로 번역되고 있다. 이 법은 항원(또는 항체)에 알칼리 포스파타아제 또는 페르옥시디아제 등의 산소를 결합시켜 두고 그 산소활성을 지표로 삼아 항원항체반응의 정도를 안 다음 여기에서 항원(또는 항체)의 양을 구하는 것이다. 이 법의 이점으로서 고감도, 조작의 간단함 및 방사선면역측정법처럼 방사성물질을 사용하지 않아도 된다는 점을 들 수 있다. 호르몬이나 면역글로불린의 정량법으로서 응용 되고 있으며 측정용 키트도 시판되고 이있다. |
||
| ESI | elastase-specific inhibitor; enzyme substrate inhibitor; epidural steroid injection |
|---|---|
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
| PI | first meiotic prophase; isoelectric point; pacing impulse; package insert; pancreatic insufficiency;... |
| EIA | electroimmunoassay; enzyme immunoassay; enzyme-linked immunosorbent assay; equine infectious anemia;... |
| PACE | Pacing and Clinical Electrophysiology; paired basic amino acid cleaving enzyme; personalized aerobic... |
| ACE inhibitor | angiotensin converting enzyme inhibitor |
|---|---|
| ACEI | Angiotensin Converting Enzyme Inhibitor |
| CEI | Converting enzyme inhibitor |
| ELISA | Enzyme Linked Immuno Sorbant Assay |
| ACE | ANG I converting enzyme |
| enzyme inhibitors | Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (12 Dec 1998) |
|---|
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
|---|---|
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |
| carbonic acid inhibitor | <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma. (27 Sep 1997) |
| carbonic anhydrase inhibitor | <pharmacology> A group of medications (sulphonamide drugs) which inhibit the enzyme carbonic anhydrase. These medications are used in the treatment of glaucoma. Examples include acetazolamide, dichlorphenamide and methazolamide. (27 Sep 1997) |
| mammary derived growth inhibitor | Fatty acid binding protein that inhibits proliferation of mammary carcinoma cells. (18 Nov 1997) |
| mechanism-based inhibitor | A competitive inhibitor that is converted to an irreversible inhibitor at the active site of the enzyme. Synonym: mechanism-based inhibitor. (05 Mar 2000) |
| glucosidase inhibitor | Agents such as acarbose which reduce gastrointestinal absorption of carbohydrates. This group of drugs has been known popularly as "starch blockers". They lower plasma glucose levels and tend to cause weight loss. A limiting side effect is flatulence. (05 Mar 2000) |
| medication, ace-inhibitor | Agents that inhibit ACE (angiotensin-converting enzyme), thereby acting as vasodilators (really as anti-vasoconstrictors), lightening the stress load on the heart. (12 Dec 1998) |
Synonyms : Inhibitors, Enzyme
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|